Palvella Therapeutics (PVLA) Operating Expenses (2016 - 2024)
Historic Operating Expenses for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to $4.4 million.
- Palvella Therapeutics' Operating Expenses rose 10795.31% to $4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $14.1 million, marking a year-over-year increase of 1875.47%. This contributed to the annual value of $14.1 million for FY2024, which is 1875.47% up from last year.
- Palvella Therapeutics' Operating Expenses amounted to $4.4 million in Q4 2024, which was up 10795.31% from $5.1 million recorded in Q3 2024.
- Palvella Therapeutics' 5-year Operating Expenses high stood at $31.3 million for Q3 2023, and its period low was -$54.9 million during Q4 2023.
- Moreover, its 5-year median value for Operating Expenses was $17.2 million (2020), whereas its average is $12.1 million.
- Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 41613.59% in 2023, then soared by 10795.31% in 2024.
- Palvella Therapeutics' Operating Expenses (Quarter) stood at $14.3 million in 2020, then surged by 36.07% to $19.4 million in 2021, then decreased by 10.68% to $17.4 million in 2022, then plummeted by 416.14% to -$54.9 million in 2023, then surged by 107.95% to $4.4 million in 2024.
- Its Operating Expenses stands at $4.4 million for Q4 2024, versus $5.1 million for Q3 2024 and $2.9 million for Q2 2024.